Overview

Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer

Status:
Completed
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
Study of Pazopanib and weekly Paclitaxel in patients with platinum resistant/refractory ovarian cancer who relapse during bevacizumab maintenance.
Phase:
Phase 2
Details
Lead Sponsor:
ARCAGY/ GINECO GROUP
Collaborator:
Novartis
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel